Skip to content

Asymmetric dimethylarginine and soluble intercellular adhesion molecule-1 serum levels alteration following ginger supplementation in patients with type 2 diabetes: A double blind, placebo-controlled, randomized clinical trial

Asymmetric dimethylarginine and soluble intercellular adhesion molecule-1 serum levels alteration following ginger supplementation in patients with type 2 diabetes: A double blind, placebo-controlled, randomized clinical trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2017012932275N1
Enrollment
45
Registered
2017-03-12
Start date
2015-11-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: Intervention group received 4 capsules of 500 mg of ginger dried powder (two with their lunch and two with the dinner) for ten weeks. To prepare supplements, dried ginger was purchased
Treatment - Drugs
Placebo
Intervention group received 4 capsules of 500 mg of ginger dried powder (two with their lunch and two with the dinner) for ten weeks. To prepare supplements, dried ginger was purchased and milled and
The participants in the placebo group were received the capsules with the same appearance of intervention capsules containing wheat flour. Placebos containing prepared in the same way in capsules with

Sponsors

Vice chancellor for research, Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Willing to cooperate; Having type 2 diabetes for 1-10 years; Adults with 30-65 years old; Both genders; Body mass index 18.5-35 kg/m2; Lack of insulin therapy and treating with glucose lowering medications Exclusion criteria: Consuming less than 90% of capsules in intervention and placebo groups; Pregnancy; Lactating; Alcohol consumption; Cigarette smoking; Insulin therapy; Hospitalization with any cause ;Ginger consumption during the intervention; Change in medication type or dosage; Change in the diet and physical activity levels

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Asymmetric Dimethylarginine. Timepoint: Before and after intervention. Method of measurement: ELISA test.;Soluble Intercellular Adhesion Molecule-1. Timepoint: Before and after intervention. Method of measurement: ELISA test.

Secondary

MeasureTime frame
Lipid rofile. Timepoint: Before and after intervention. Method of measurement: ELISA.;Anthropometric measures. Timepoint: Before and after intervention. Method of measurement: Caliper and .

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMeysam Zarezadeh

Tehran University of Medical Sciences

meysam.za93@gmail.com+98 41 3386 1877

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026